COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide; developed as TransCon PTH) is now commercially ...

JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...

TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

The company has already demonstrated the value of its technology in two approved products, namely Yorvipath (palopegteriparatide), a modified version of parathyroid hormone (PTH), which is for the ...

A webcast replay will also be available COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed ...

In addition to SKYTROFA, YORVIPATH was also a strong contender as it generated a revenue of €8.5 million during the quarter. Management on December 19 announced the launch of YORVIPATH in the ...

“Ascendis is well-positioned for rapid revenue growth with the launch of our first two Endocrinology Rare Disease medicines, SKYTROFA and YORVIPATH, and, following our pre-NDA meeting, planned ...

CEO Jan Mikkelsen expressed confidence in the company’s growth trajectory, reporting estimated revenues of €202 million for SKYTROFA in 2024, and €29 million for YORVIPATH, with significant ...

COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.